LUNGONCOLOGY~PROGRESSNOTE||Pt58Mwithcoughshortness§breathpresented03/2024CTchestshowed6.7cmleftupperlobemass+mediast1naladenopathy(stations4L,7)PETavid§SUVmax18.2Bronchoscopyendobronch1albiopsy:adenocarc1noma,poorlydifferentiatedTTF1+CK7+napsinA+

MOLECULAR:NGSpanelreturned04/15/2024EGFRwildtypeALKnegativeROS1negativeKRASmutG12C(VAF48%)STK11lossBRAFwildtypeMETamp(copynumber=6)RETnegativePDL1TPS45%TMB12mut/Mb

STAGING:Clinicastage~cT3N2M0StageIIIBbasedonimagingMediastinoscopy04/22/2024:station7LNpositive3/3coresPatho1ogicstagecT3N2M0(confirmed)

PatientEvaluation:ECOG1,weighloss12lbsover2months,moderatesmoker(30pack-yrs,quittedOctober2023)PFTs:FEV168%predicted,renalfunction:CrCl85mL/min

TREATMENTPLANenrol1edinKEYNOTE-671trial(NCT03425643)perioperativepembrolizumab+chemotherapy~randomizedneoadjuvantarmStartdate05/01/2024Regimen:pembrolizumab200mgQ3W+cisplatin75mg/m2+pemetrexed500mg/m2

Cycle1(05/01/24)&Cycle2(05/22/24):welltoleratedminimalgrade1nauseaCycle3(06/12/24):developedGrade2||pneumonitis~coughfeverdyspnea,CTshowedground-glassopacitiesbi1ateralPembrolizumabHELDsteroids(prednisone1mg/kgstarted)improvedover2weeksCycle4SKIPPED

Cycle5(07/24/24)~pneumonitisresolvedresumedpembrolizumab+chemoONLY2morecycles(total4cycleschemocompleted,pembrolizumabcontinued)RestagingCT09/2024:partialmresponsetumor3.2cm(from6.7cm)mediast1nalnodesstable

Surgery:10/15/2024leftupperlobectomy+mediast1nallymphnodedissectionPATHOLOGY~Adenocarc1noma2.8cmresidualtumor,moderatelydifferentiatedypT2aN0M0(0/18lymphnodespositive!)pathologiccompleteresponse1nnodes!margins:negativeLVI:absentVPI:absentResidualviabletumor:~40%Major~pathologicresponse(MPR)achieved

POSTOPrecoverycomplicatedbyproIongedairleak(12days)requiringpleurx§catheterplacement+Grade2atrialfib(newonset)requiringmetoprololEventua11yresolved